# Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer

> **NCT01623102** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin and gemcitabine combination with Bevacizumab
- **DRUG:** Gemcitabine combined with cisplatin chemotherapy

## Key facts

- **NCT ID:** NCT01623102
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623102, "Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01623102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*